LINEAGE CELL THERAPEUTICS IN (LCTX)

Thursday Sector Laggards: Shipping, Biotechnology Stocks

Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes.

These stocks are moving in today's session

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.

Gapping stocks in Wednesday's session

Gap analysis on 2024-11-20: gap up and gap down stocks in today's session.

Which stocks are moving before the opening bell on Wednesday?

Stay updated with the stocks that are on the move in Wednesday's pre-market session.

Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering

Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit

OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium

Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop

Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

LCTX Stock Earnings: Lineage Cell Therapeutics Beats EPS, Beats Revenue for Q2 2024

LCTX stock results show that Lineage Cell Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Lineage Cell Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index

Lineage to Present at 2024 BIO International Convention

Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

LCTX Stock Earnings: Lineage Cell Therapeutics Meets EPS, Beats Revenue for Q1 2024

LCTX stock results show that Lineage Cell Therapeutics met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)

Lineage Announces Changes to Board of Directors

Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium

RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting

LCTX Stock Earnings: Lineage Cell Therapeutics Beats EPS, Beats Revenue for Q4 2023

LCTX stock results show that Lineage Cell Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024

Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury

Friday 2/9 Insider Buying Report: BRTX, LCTX

Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering

Lineage Cell Therapeutics looks to raise $14M through direct offering (NYSE:LCTX)

Lineage Cell Therapeutics announces a registered direct offering of 13.46M shares at $1.04 per share, resulting in $14M gross proceeds.

Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering